Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID05015348

Effects of Omega-3 Polyenoic Acid on Blood Lipid, Inflammatory Factors and Body Composition in Patients with Hyperlipidemia

Led by Peking Union Medical College Hospital · Updated on 2025-01-01

120

Participants Needed

1

Research Sites

43 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the effects of Omega-3 polyunsaturated fatty acids (PUFA) on blood lipids, inflammatory factors, and body composition in patients diagnosed with hyperlipidemia. This study compares an intervention group receiving Omega-3 PUFA with a control group receiving a placebo. Both groups also receive nutritional counseling and education about a low-fat diet to support their health during the study. Participants in the intervention group will take 3.6 grams per day of fish oil containing Omega-3 PUFA (EPA+DHA), while the control group will receive a placebo made to look identical but containing palm oil. The study is randomized and blinded to ensure unbiased results. Assessments will take place before treatment, at the midpoint, and at the end of the study to monitor changes in lipids, inflammatory markers, weight, and body composition. During the study, researchers will measure triglycerides, cholesterol, LDL cholesterol, inflammatory markers such as TNF-alpha, hsCRP, and interleukin-6, as well as body weight and BMI over a three-month period. Secondary outcomes include adiponectin and leptin levels. Participants will have regular visits for these assessments, and their adherence to the treatment and diet will be monitored throughout the study duration.

CONDITIONS

Brief Title

Effects of Omega-3 PUFA on Lipids, Inflammatory Factors and Body Composition in Patients with Hyperlipidemia

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female aged 18 years or older
  • Diagnosed with hyperlipidemia meeting clinical criteria: triglycerides ≥1.7 mmol/L, or total cholesterol ≥5.2 mmol/L, or LDL cholesterol ≥3.4 mmol/L
  • Fully understand and voluntarily sign the informed consent
  • Able to eat orally
  • Able to complete the study and follow researchers' instructions
Not Eligible

You will not qualify if you...

  • Currently taking lipid-lowering drugs
  • Hyperlipidemia caused by secondary conditions such as nephrotic syndrome, hypothyroidism, renal failure, liver disease, systemic lupus erythematosus, glycogen storage disease, myeloma, fat atrophy, acute porphyria, polycystic ovary syndrome
  • Use of diuretics, non-cardiac selective beta blockers, or glucocorticoids that may cause secondary dyslipidemia
  • Severe internal or external diseases including heart, liver, kidney dysfunction, recent acute myocardial infarction, stroke, intracerebral hemorrhage, COPD attack, respiratory failure within 3 months
  • Surgery within the last 3 months
  • Hemorrhagic disease or bleeding tendency
  • History of allergy to omega-3 polyenoic acid
  • Pregnant or breastfeeding women
  • Poor compliance or unable to complete follow-up
  • Serious abnormal metabolism or need for further intervention making continuation unsuitable as judged by physician

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 3 months

Participants take either Omega-3 PUFA or placebo daily while receiving nutritional counseling and education for a low-fat diet. Lipids, inflammatory factors, weight, and body composition are assessed.

3 visits (beginning, middle, and end of treatment)

Trial Site Locations

Total: 1 location

1

Peking Union Medical College Hospita

Beijing, Beijing Municipality, China, 100730

Actively Recruiting

Loading map...

Research Team

K

Kang Yu, master

F

Fang Wang, master

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Single-dose, Open-label Phase I Trial Comparing Pharmacoki...

Hyperlipidemias

Actively Recruiting

1 location

The Role of Akkermansia Muciniphilia in Combating the Metabo...

Prostate Cancer

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here